Boehringer Ingelheim and Lilly announced the launch of Synjardy XR (empagliflozin and metformin HCl extended-release) tablets as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both empagliflozin and metformin HCl is appropriate.
Synjardy XR combines empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease but the efficacy of Synjardy XR has not been established for this indication.
The Food and Drug Administration (FDA) initially approved Synjardy XR in December 2016. Both Synjardy and Synjardy XR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. It carries a boxed warning regarding metformin-associated lactic acidosis.
Synjardy XR is available in 5mg/1000mg and 12.5mg/1000mg strength tablets in 180-count bottles, and as 10mg/1000mg and 25mg/1000mg strength tablets in 30-count and 90-count bottles. Synjardy is already available as 5mg/500mg, 12.5mg/500mg, 5mg/1000mg, and 12.5mg/1000mg strength tablets in 60- and 180-count bottles.
For more information call (800) 542-6257 or visit SynjardyXR.com.